Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 1490738, 14 pages
http://dx.doi.org/10.1155/2016/1490738
Review Article

Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells

1Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. 5 Beixiange, Xicheng District, Beijing 100053, China
2Beijing University of Chinese Medicine, No. 11 North Third Ring Road East, Chaoyang District, Beijing 100029, China
3China Academy of Chinese Medical Sciences, No. 16 Nanxiaojie Dongzhimennei, Dongcheng District, Beijing 100700, China

Received 25 December 2015; Accepted 26 January 2016

Academic Editor: Kallesh D. Jayappa

Copyright © 2016 Jingnan Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Seretis, C. Seretis, H. Youssef, and M. Chapman, “Colorectal cancer: seed and soil hypothesis revisited,” Anticancer Research, vol. 34, no. 5, pp. 2087–2094, 2014. View at Google Scholar · View at Scopus
  2. I. J. Fidler, “The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited,” Nature Reviews Cancer, vol. 3, no. 6, pp. 453–458, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Diao, J. Zhao, E. Winter, and M. S. Cattral, “Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1+ conventional dendritic cells through IL-6,” The Journal of Immunology, vol. 186, no. 9, pp. 5058–5067, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. O. Oluwadara, L. Giacomelli, X. Brant et al., “The role of the microenvironment in tumor immune surveillance,” Bioinformation, vol. 5, no. 7, pp. 285–290, 2011. View at Publisher · View at Google Scholar
  5. S. Chabot, N. Jabrane-Ferrat, K. Bigot et al., “A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor,” The Journal of Experimental Medicine, vol. 208, no. 5, pp. 973–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. E. T. Shinohara and A. Maity, “Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment,” Current Molecular Medicine, vol. 9, no. 9, pp. 1034–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Lu, W. Su, Z.-H. Miao, H.-R. Niu, J. Liu, and Q.-L. Hua, “Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer,” Chinese Journal of Integrative Medicine, vol. 14, no. 1, pp. 33–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Wang and J. Cui, “Treatment of mid-late stage NSCLC using sodium cantharidinate/vitamin B6/GP regimen in clinic,” Journal of Cancer Research and Therapeutics, vol. 10, no. 5, pp. 79–81, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Guo, S.-P. Bai, L. Zhao, and X.-H. Wang, “Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival,” Medical Oncology, vol. 29, no. 3, pp. 1656–1662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. L. W. Ruan and Y. C. Deng, “Study on effect of Xiaoaiping in enhancing efficacy of neoadjuvant chemotherapy for breast cancer and its mechanism,” Zhongguo Zhong Yao Za Zhi, vol. 40, no. 4, pp. 749–752, 2015. View at Google Scholar
  11. Y. Liu, Z. W. Jia, L. Dong, R. Wang, and G. Q. Qiu, “A randomized pilot study of atractylenolide I on gastric cancer cachexia patients,” Evidence-Based Complementary and Alternative Medicine, vol. 5, no. 3, pp. 337–344, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Zhong, H.-D. Li, D.-Y. Liu et al., “Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 14, pp. 5951–5957, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. T.-J. Qin, X.-H. Zhao, J. Yun, L.-X. Zhang, Z.-P. Ruan, and B.-R. Pan, “Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5210–5216, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. I. James, C. Iwuji, G. Irving et al., “Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy,” Cancer Letters, vol. 364, no. 2, pp. 135–141, 2015. View at Publisher · View at Google Scholar
  15. D.-R. Lu, D.-Y. Li, X.-Y. Chen, P.-Z. Ye, and S.-D. Tian, “Clinical research of compound Zhebei granules for increasing the therapeutic effect of chemotherapy in refractory acute leukemia patients,” Journal of Traditional Chinese Medicine, vol. 29, no. 3, pp. 190–194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Jia, Q. Guan, Y. Guo, and C. Du, “Reduction of inflammatory hyperplasia in the intestine in colon cancer-prone mice by water-extract of Cistanche deserticola,” Phytotherapy Research, vol. 26, no. 6, pp. 812–819, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Sun, “Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures,” Medicinal Research Reviews, vol. 35, no. 2, pp. 408–436, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Li, L. Li, R. Liu, and H.-S. Lin, “Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology,” Chinese Journal of Integrative Medicine, vol. 18, no. 10, pp. 730–736, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. M. W. Pickup, J. K. Mouw, and V. M. Weaver, “The extracellular matrix modulates the hallmarks of cancer,” EMBO Reports, vol. 15, no. 12, pp. 1243–1253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Lu, V. M. Weaver, and Z. Werb, “The extracellular matrix: a dynamic niche in cancer progression,” The Journal of Cell Biology, vol. 196, no. 4, pp. 395–406, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Giussani, G. Merlino, V. Cappelletti, E. Tagliabue, and M. G. Daidone, “Tumor-extracellular matrix interactions: identification of tools associated with breast cancer progression,” Seminars in Cancer Biology, vol. 35, pp. 3–10, 2015. View at Publisher · View at Google Scholar
  22. A. W. Holle, J. L. Young, and J. P. Spatz, “In vitro cancer cell-ECM interactions inform in vivo cancer treatment,” Advanced Drug Delivery Reviews, vol. 97, pp. 270–279, 2016. View at Publisher · View at Google Scholar
  23. C. A. Sherman-Baust, A. T. Weeraratna, L. B. A. Rangel et al., “Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells,” Cancer Cell, vol. 3, no. 4, pp. 377–386, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. W. Deng, H. Sui, Q. Wang et al., “A Chinese herbal formula, Yi-Qi-Fu-Sheng, inhibits migration/invasion of colorectal cancer by down-regulating MMP-2/9 via inhibiting the activation of ERK/MAPK signaling pathways,” BMC Complementary and Alternative Medicine, vol. 13, article 65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Zhou, L. Xu, M. Ye, M. Liao, H. Du, and H. Chen, “Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways,” Hormone and Metabolic Research, vol. 46, no. 11, pp. 753–760, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Zheng, Y.-M. Zhang, Y.-Z. Zhan, and C.-X. Liu, “Momordica cochinchinensis seed extracts suppress migration and invasion of human breast cancer ZR-75-30 cells via down-regulating MMP-2 and MMP-9,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 3, pp. 1105–1110, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Kroemer, G. Mariño, and B. Levine, “Autophagy and the integrated stress response,” Molecular Cell, vol. 40, no. 2, pp. 280–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Vaupel, M. Höckel, and A. Mayer, “Detection and characterization of tumor hypoxia using pO2 histography,” Antioxidants and Redox Signaling, vol. 9, no. 8, pp. 1221–1235, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Yu, J. W. Rak, B. L. Coomber, D. J. Hicklin, and R. S. Kerbel, “Effect of p53 status on tumor response to antiangiogenic therapy,” Science, vol. 295, no. 5559, pp. 1526–1528, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. X. Yang, D.-D. Yu, F. Yan et al., “The role of autophagy induced by tumor microenvironment in different cells and stages of cancer,” Cell & Bioscience, vol. 5, article 14, 2015. View at Publisher · View at Google Scholar
  31. Z. Zhou, H. Liu, X. Chi et al., “A protein-corona-free T1T2 dual-modal contrast agent for accurate imaging of lymphatic tumor metastasis,” ACS Applied Materials & Interfaces, vol. 7, no. 51, pp. 28286–28293, 2015. View at Publisher · View at Google Scholar
  32. R. Kalluri and R. A. Weinberg, “The basics of epithelial-mesenchymal transition,” The Journal of Clinical Investigation, vol. 119, no. 6, pp. 1420–1428, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Lv, S. Zhao, J. Han, L. Zheng, Z. Yang, and L. Zhao, “Hypoxia-inducible factor-1α induces multidrug resistance protein in colon cancer,” OncoTargets and Therapy, vol. 8, pp. 1941–1948, 2015. View at Publisher · View at Google Scholar
  34. E. A. Turley, M. Veiseh, D. C. Radisky, and M. J. Bissell, “Mechanisms of disease: epithelial-mesenchymal transition—does cellular plasticity fuel neoplastic progression?” Nature Clinical Practice Oncology, vol. 5, no. 5, pp. 280–290, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Chen, A. Shen, Y. Zhang et al., “Pien Tze Huang inhibits hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells through suppression of the HIF-1 pathway,” Experimental and Therapeutic Medicine, vol. 7, no. 5, pp. 1237–1242, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Dai, Q. Yin, L. Wei et al., “Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells,” Molecular Carcinogenesis, 2015. View at Publisher · View at Google Scholar
  37. K. Zhao, X. Song, Y. Huang et al., “Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling,” European Journal of Pharmacology, vol. 737, pp. 57–69, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Wang, L. Zhao, L.-T. Zhu et al., “Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway,” Molecular Carcinogenesis, vol. 53, no. 1, pp. E107–E118, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Bellone, A. Carbone, C. Smirne et al., “Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells,” The Journal of Immunology, vol. 177, no. 5, pp. 3448–3460, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. B.-N. Lee, M. Follen, G. Rodriquez et al., “Deficiencies in myeloid antigen-presenting cells in women with cervical squamous intraepithelial lesions,” Cancer, vol. 107, no. 5, pp. 999–1007, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Perrot, D. Blanchard, N. Freymond et al., “Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage,” The Journal of Immunology, vol. 178, no. 5, pp. 2763–2769, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. L. A. Ormandy, A. Färber, T. Cantz et al., “Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 20, pp. 3275–3282, 2006. View at Google Scholar · View at Scopus
  43. D. Gabrilovich, “Mechanisms and functional significance of tumour-induced dendritic-cell defects,” Nature Reviews Immunology, vol. 4, no. 12, pp. 941–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Tian, X. Li, H. Li, Q. Lu, G. Sun, and H. Chen, “Astragalus mongholicus regulate the Toll-like-receptor 4 meditated signal transduction of dendritic cells to restrain stomach cancer cells,” African Journal of Traditional, Complementary and Alternative Medicines, vol. 11, no. 3, pp. 92–96, 2014. View at Publisher · View at Google Scholar
  45. J. E. Talmadge and D. I. Gabrilovich, “History of myeloid-derived suppressor cells,” Nature Reviews Cancer, vol. 13, no. 10, pp. 739–752, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Schiavoni, L. Gabriele, and F. Mattei, “The tumor microenvironment: a pitch for multiple players,” Frontiers in Oncology, vol. 3, article 90, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Wang, Y. Li, W. Wang, M. Zhou, and Z. Cao, “Compound K suppresses myeloid-derived suppressor cells in a mouse model bearing CT26 colorectal cancer xenograft,” Nan Fang Yi Ke Da Xue Xue Bao, vol. 35, no. 5, pp. 748–752, 2015. View at Google Scholar
  48. B. Ruffell, N. I. Affara, and L. M. Coussens, “Differential macrophage programming in the tumor microenvironment,” Trends in Immunology, vol. 33, no. 3, pp. 119–126, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. B.-Z. Qian and J. W. Pollard, “Macrophage diversity enhances tumor progression and metastasis,” Cell, vol. 141, no. 1, pp. 39–51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. W. Pollard, “Trophic macrophages in development and disease,” Nature Reviews Immunology, vol. 9, no. 4, pp. 259–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Solinas, G. Germano, A. Mantovani, and P. Allavena, “Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation,” Journal of Leukocyte Biology, vol. 86, no. 5, pp. 1065–1073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. S. F. Schoppmann, P. Birner, J. Stöckl et al., “Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis,” The American Journal of Pathology, vol. 161, no. 3, pp. 947–956, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Y. Tan, N. Wang, K. Man, S. W. Tsao, C. M. Che, and Y. Feng, “Autophagy-induced RelB/p52 activation mediates tumour-associated macrophage repolarisation and suppression of hepatocellular carcinoma by natural compound baicalin,” Cell Death & Disease, vol. 6, no. 10, Article ID e1942, 2015. View at Publisher · View at Google Scholar
  54. S.-Q. Gong, W. Sun, M. Wang, and Y.-Y. Fu, “Role of TLR4 and TCR or BCR against baicalin-induced responses in T and B cells,” International Immunopharmacology, vol. 11, no. 12, pp. 2176–2180, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. X. Qi, G. Liu, L. Qiu, X. Lin, and M. Liu, “Marine bromophenol bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, represses angiogenesis in HUVEC cells and in zebrafish embryos via inhibiting the VEGF signal systems,” Biomedicine & Pharmacotherapy, vol. 75, pp. 58–66, 2015. View at Publisher · View at Google Scholar
  56. Y.-C. Hseu, S.-C. Chen, W.-H. Lin et al., “Toona sinensis (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells,” Journal of Ethnopharmacology, vol. 134, no. 1, pp. 111–121, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. N. Ferrara, “Vascular endothelial growth factor: basic science and clinical progress,” Endocrine Reviews, vol. 25, no. 4, pp. 581–611, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. C. I. M. Baeten, F. Hillen, P. Pauwels, A. P. de Bruine, and C. G. M. I. Baeten, “Prognostic role of vasculogenic mimicry in colorectal cancer,” Diseases of the Colon and Rectum, vol. 52, no. 12, pp. 2028–2035, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Sun, S. Zhang, D. Zhang et al., “Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma,” Oncology Reports, vol. 16, no. 4, pp. 693–698, 2006. View at Google Scholar · View at Scopus
  60. M. Li, Y. Gu, Z. Zhang et al., “Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma,” Pathology and Oncology Research, vol. 16, no. 2, pp. 259–266, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J.-M. Lü, Q. Yao, and C. Chen, “Ginseng compounds: an update on their molecular mechanisms and medical applications,” Current Vascular Pharmacology, vol. 7, no. 3, pp. 293–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. D. F. Zeng, J. L. Wang, P. Y. Kong, C. Chang, J. Li, and J. Li, “Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 5, pp. 2172–2178, 2014. View at Google Scholar · View at Scopus
  63. N. Koonrungsesomboon, K. Na-Bangchang, and J. Karbwang, “Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC,” Asian Pacific Journal of Tropical Medicine, vol. 7, no. 6, pp. 421–428, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Wang, R. Cai, J. Ma et al., “The natural compound codonolactone impairs tumor induced angiogenesis by downregulating BMP signaling in endothelial cells,” Phytomedicine, vol. 22, no. 11, pp. 1017–1026, 2015. View at Publisher · View at Google Scholar
  65. J.-M. Lin, L.-H. Wei, Y.-Q. Chen et al., “Pien Tze Huang (片仔癀)-induced apoptosis in human colon cancer HT-29 cells is associated with regulation of the Bcl-2 family and activation of caspase 3,” Chinese Journal of Integrative Medicine, vol. 17, no. 9, pp. 685–690, 2011. View at Publisher · View at Google Scholar
  66. Q. Zhuang, F. Hong, A. Shen et al., “Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model,” International Journal of Oncology, vol. 40, no. 5, pp. 1569–1574, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. A.-L. Shen, F. Hong, L.-Y. Liu et al., “Effects of Pien Tze Huang on angiogenesis in vivo and in vitro,” Chinese Journal of Integrative Medicine, vol. 18, no. 6, pp. 431–436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. A. Shen, F. Hong, L. Liu et al., “Pien Tze Huang inhibits the proliferation of human colon carcinoma cells by arresting G1/S cell cycle progression,” Oncology Letters, vol. 4, no. 4, pp. 767–770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Shen, J. Lin, Y. Chen et al., “Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways,” Oncology Reports, vol. 30, no. 4, pp. 1701–1706, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. A. Shen, Y. Chen, F. Hong et al., “Pien Tze Huang suppresses IL-6-inducible STAT3 activation in human colon carcinoma cells through induction of SOCS3,” Oncology Reports, vol. 28, no. 6, pp. 2125–2130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. G. W. Yang, J. S. Jiang, and W. Q. Lu, “Ferulic acid exerts anti-angiogenic and anti-tumor activity by targeting fibroblast growth factor receptor 1-mediated angiogenesis,” International Journal of Molecular Sciences, vol. 16, no. 10, pp. 24011–24031, 2015. View at Publisher · View at Google Scholar
  72. W. Zheng, A. Aspelund, and K. Alitalo, “Lymphangiogenic factors, mechanisms, and applications,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 878–887, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Karaman and M. Detmar, “Mechanisms of lymphatic metastasis,” The Journal of Clinical Investigation, vol. 124, no. 3, pp. 922–928, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. X. Kang, J. Kim, M. Deng et al., “Inhibitory leukocyte immunoglobulin-like receptors: immune checkpoint proteins and tumor sustaining factors,” Cell Cycle, vol. 15, no. 1, pp. 25–40, 2016. View at Publisher · View at Google Scholar
  75. Y. Kimura and M. Sumiyoshi, “Anti-tumor and anti-metastatic actions of wogonin isolated from Scutellaria baicalensis roots through anti-lymphangiogenesis,” Phytomedicine, vol. 20, no. 3-4, pp. 328–336, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. Y.-Z. Fan, J.-Y. Fu, Z.-M. Zhao, and C.-Q. Chen, “Inhibitory effect of norcantharidin on the growth of human gallbladder carcinoma GBC-SD cells in vitro,” Hepatobiliary & Pancreatic Diseases International, vol. 6, no. 1, pp. 72–80, 2007. View at Google Scholar · View at Scopus
  77. Y.-Z. Fan, Z.-M. Zhao, J.-Y. Fu, C.-Q. Chen, and W. Sun, “Norcantharidin inhibits growth of human gallbladder carcinoma xenografted tumors in nude mice by inducing apoptosis and blocking the cell cycle in vivo,” Hepatobiliary & Pancreatic Diseases International, vol. 9, no. 4, pp. 414–422, 2010. View at Google Scholar · View at Scopus
  78. C.-C. Yu, F.-Y. Ko, C.-S. Yu et al., “Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROS-modulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells,” International Journal of Oncology, vol. 41, no. 3, pp. 1050–1060, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. S.-H. Kok, S.-J. Cheng, C.-Y. Hong et al., “Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio,” Cancer Letters, vol. 217, no. 1, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. Y.-P. Ho, K. K. W. To, S. C. F. Au-Yeung, X. Wang, G. Lin, and X. Han, “Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional chinese medicine, with a platinum moiety,” Journal of Medicinal Chemistry, vol. 44, no. 13, pp. 2065–2068, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. J. A. Nagy, E. Vasile, D. Feng et al., “Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis,” The Journal of Experimental Medicine, vol. 196, no. 11, pp. 1497–1506, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Räßler, U. Voigt, S. Metz, P. Elsner, and S. Schliemann, “Fast-growing tumor of the eyelid,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 14, no. 1, pp. 81–84, 2016. View at Publisher · View at Google Scholar
  83. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. V. Catalano, A. Turdo, S. Di Franco, F. Dieli, M. Todaro, and G. Stassi, “Tumor and its microenvironment: a synergistic interplay,” Seminars in Cancer Biology, vol. 23, no. 6, pp. 522–532, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Wang, X. Wu, M. Tan et al., “Fighting fire with fire: poisonous Chinese herbal medicine for cancer therapy,” Journal of Ethnopharmacology, vol. 140, no. 1, pp. 33–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. F. He, H.-N. Wu, M.-Y. Cai et al., “Inhibition of ovarian cancer cell proliferation by Pien Tze Huang via the AKT-mTOR pathway,” Oncology Letters, vol. 7, no. 6, pp. 2047–2052, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. E. Hervouet, M. Cheray, F. M. Vallette, and P. Cartron, “DNA methylation and apoptosis resistance in cancer cells,” Cells, vol. 2, no. 3, pp. 545–573, 2013. View at Publisher · View at Google Scholar
  88. C.-M. Hsu, Y. Tsai, L. Wan, and F.-J. Tsai, “Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells,” International Journal of Oncology, vol. 43, no. 1, pp. 338–348, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. B. Wang, Q. Han, and Y. Zhu, “Oxymatrine inhibited cell proliferation by inducing apoptosis in human lung cancer A549 cells,” Bio-Medical Materials and Engineering, vol. 26, pp. S165–S172, 2015. View at Publisher · View at Google Scholar
  90. D. A. Liebermann, B. Hoffman, and D. Vesely, “p53 induced growth arrest versus apoptosis and its modulation by survival cytokines,” Cell Cycle, vol. 6, no. 2, pp. 166–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Liu, J.-G. Wang, S.-Y. Wang, Y. Li, Y.-P. Wu, and S.-M. Xi, “Antitumor effect and mechanism of Gecko on human esophageal carcinoma cell lines in vitro and xenografted sarcoma 180 in Kunming mice,” World Journal of Gastroenterology, vol. 14, no. 25, pp. 3990–3996, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Ma and W. Li, “Emodin inhibits LOVO colorectal cancer cell proliferation via the regulation of the Bcl-2/Bax ratio and cytochrome c,” Experimental and Therapeutic Medicine, vol. 8, no. 4, pp. 1225–1228, 2014. View at Publisher · View at Google Scholar · View at Scopus
  93. R. M. Mohammad, I. Muqbil, L. Lowe et al., “Broad targeting of resistance to apoptosis in cancer,” Seminars in Cancer Biology, vol. 35, supplement, pp. S78–S103, 2015. View at Google Scholar
  94. P. Plastina, D. Bonofiglio, D. Vizza et al., “Identification of bioactive constituents of Ziziphus jujube fruit extracts exerting antiproliferative and apoptotic effects in human breast cancer cells,” Journal of Ethnopharmacology, vol. 140, no. 2, pp. 325–332, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. B. Wang, Q. Han, and Y. Zhu, “Oxymatrine inhibited cell proliferation by inducing apoptosis in human lung cancer A549 cells,” Bio-Medical Materials and Engineering, vol. 26, supplement 1, pp. S165–S172, 2015. View at Publisher · View at Google Scholar
  96. L. Chu, H. Zhao, J. Fang et al., “The traditional Chinese medicinal formula BDL301 suppresses tumor growth by inhibiting STAT3 pathway and inducing apoptosis in colorectal cancer cells,” DNA and Cell Biology, vol. 34, no. 3, pp. 178–188, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. X.-Y. Dang, L. Dong, H.-T. Shi, and B.-C. Zou, “Effects of serum containing Chinese medicine Sanpi Pingwei (散癖平胃) formula on proliferation and apoptosis of human SGC-7901 cells,” Chinese Journal of Integrative Medicine, vol. 19, no. 2, pp. 119–126, 2013. View at Publisher · View at Google Scholar
  98. N. Li, D. Zheng, J. Xue et al., “Cidan inhibits liver cancer cell growth by reducing COX-2 and VEGF expression and cell cycle arrest,” Experimental and Therapeutic Medicine, vol. 9, no. 5, pp. 1709–1718, 2015. View at Publisher · View at Google Scholar
  99. W. Liu, S. Y. Li, X. E. Huang, J. J. Cui, T. Zhao, and H. Zhang, “Inhibition of tumor growth in vitro by a combination of extracts from Rosa roxburghii Tratt and Fagopyrum cymosum,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2409–2414, 2012. View at Publisher · View at Google Scholar
  100. Y.-L. Hsu, M.-H. Yen, P.-L. Kuo et al., “San-Zhong-Kui-Jian-Tang, a traditional Chinese medicine prescription, inhibits the proliferation of human breast cancer cell by blocking cell cycle progression and inducing apoptosis,” Biological & Pharmaceutical Bulletin, vol. 29, no. 12, pp. 2388–2394, 2006. View at Publisher · View at Google Scholar · View at Scopus
  101. X. S. Chai, X. X. Zhang, and W. Y. Wu, “Xiaoji Decoction inhibited cell proliferation and induced apoptosis through Akt signaling pathway in human lung cancer A549 cells,” Chinese Journal of Integrative Medicine, vol. 20, no. 9, pp. 701–705, 2014. View at Publisher · View at Google Scholar
  102. S.-Y. Xi, Y.-H. Teng, Y. Chen et al., “Jianpi Huayu Decoction inhibits proliferation in human colorectal cancer cells (SW480) by inducing G0/G1-phase cell cycle arrest and apoptosis,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 236506, 8 pages, 2015. View at Publisher · View at Google Scholar
  103. L. Zhang, W. Tian, S. Kim, W. Ding, Y. Tong, and S. Chen, “Arsenic sulfide, the main component of realgar, a traditional Chinese medicine, induces apoptosis of gastric cancer cells in vitro and in vivo,” Drug Design Development and Therapy, vol. 9, pp. 79–92, 2015. View at Publisher · View at Google Scholar
  104. M. Qiao, S. Sheng, and A. B. Pardee, “Metastasis and AKT activation,” Cell Cycle, vol. 7, no. 19, pp. 2991–2996, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. J. K. Beatty, A. Bhargava, and A. G. Buret, “Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection,” World Journal of Gastroenterology, vol. 20, no. 14, pp. 3976–3985, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. Z. Liu, Z. Liu, X. Zhang, P. Xue, and H. Zhang, “RY10-4 suppressed metastasis of MDA-MB-231 by stabilizing ECM and E-cadherin,” Biomedicine & Pharmacotherapy, vol. 68, no. 4, pp. 439–445, 2014. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Zhang, J. Liu, J. Kou, J. Yu, and B. Yu, “DT-13 suppresses MDA-MB-435 cell adhesion and invasion by inhibiting MMP-2/9 via the p38 MAPK pathway,” Molecular Medicine Reports, vol. 6, no. 5, pp. 1121–1125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. X. Liu, R. Dong, Z. Jiang et al., “MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition,” Tumor Biology, vol. 36, no. 6, pp. 4261–4269, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. M. S. Tretiakova, J. Hart, M. T. Shabani-Rad, J. Zhang, and Z.-H. Gao, “Distinction of hepatocellular adenoma from hepatocellular carcinoma with and without cirrhosis using E-cadherin and matrix metalloproteinase immunohistochemistry,” Modern Pathology, vol. 22, no. 8, pp. 1113–1120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. M. Arechederra, N. Priego, A. Vázquez-Carballo et al., “p38 MAPK down-regulates fibulin 3 expression through methylation of gene regulatory sequences: role in migration and invasion,” The Journal of Biological Chemistry, vol. 290, no. 7, pp. 4383–4397, 2015. View at Publisher · View at Google Scholar
  111. W. Li, C. Chen, S. M. Saud et al., “Fei-Liu-Ping ointment inhibits lung cancer growth and invasion by suppressing tumor inflammatory microenvironment,” BMC Complementary and Alternative Medicine, vol. 14, article 153, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. Y.-W. Chiu, T.-H. Lin, W.-S. Huang et al., “Baicalein inhibits the migration and invasive properties of human hepatoma cells,” Toxicology and Applied Pharmacology, vol. 255, no. 3, pp. 316–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. Y. Ohashi, Y. Tsuchiya, K. Koizumi, H. Sakurai, and I. Saiki, “Prevention of intrahepatic metastasis by curcumin in an orthotopic implantation model,” Oncology, vol. 65, no. 3, pp. 250–258, 2003. View at Publisher · View at Google Scholar · View at Scopus
  114. D. S. Vinay, E. P. Ryan, G. Pawelec et al., “Immune evasion in cancer: mechanistic basis and therapeutic strategies,” Seminars in Cancer Biology, vol. 35, supplement, pp. S185–S198, 2015. View at Publisher · View at Google Scholar
  115. J. B. Swann and M. J. Smyth, “Immune surveillance of tumors,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1137–1146, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. J. W. Shay and I. B. Roninson, “Hallmarks of senescence in carcinogenesis and cancer therapy,” Oncogene, vol. 23, no. 16, pp. 2919–2933, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. Q. Guo, J. Li, and H. Lin, “Effect and molecular mechanisms of traditional chinese medicine on regulating tumor immunosuppressive microenvironment,” BioMed Research International, vol. 2015, Article ID 261620, 12 pages, 2015. View at Publisher · View at Google Scholar
  118. M. Campoli and S. Ferrone, “Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands,” Tissue Antigens, vol. 72, no. 4, pp. 321–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. Y.-L. Li, B.-G. Sun, T. Xiang, Z.-X. Chen, and S.-J. Zhang, “Effect of invigorating spleen and detoxification decoction on MHC I/MHC II in spleen-deficiency liver cancer rats survival,” Journal of Chinese Medicinal Materials, vol. 37, no. 3, pp. 454–460, 2014. View at Google Scholar · View at Scopus
  120. M. Villa-Morales and J. Fernández-Piqueras, “Targeting the Fas/FasL signaling pathway in cancer therapy,” Expert Opinion on Therapeutic Targets, vol. 16, no. 1, pp. 85–101, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Reichmann, “The biological role of the Fas/FasL system during tumor formation and progression,” Seminars in Cancer Biology, vol. 12, no. 4, pp. 309–315, 2002. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Li, G.-Z. Sun, H.-S. Lin et al., “The herb medicine formula ‘Yang Wei Kang Liu’ improves the survival of late stage gastric cancer patients and induces the apoptosis of human gastric cancer cell line through Fas/Fas ligand and Bax/Bcl-2 pathways,” International Immunopharmacology, vol. 8, no. 9, pp. 1196–1206, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Kedmi, A. Avigdor, and A. Nagler, “Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities,” Acta Haematologica, vol. 133, no. 2, pp. 129–135, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, “PD-1 and its ligands in tolerance and immunity,” Annual Review of Immunology, vol. 26, pp. 677–704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  125. J. R. Wang, J. Y. Wang, T. T. Zhang, and X. D. Cheng, “Regulate molecular expression of PD-1/PD-Ls by Astragalus polysaccharides on melanoma mice,” Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai, vol. 28, no. 5, pp. 74–79, 2014. View at Google Scholar
  126. J. Gu, X. Fang, J. Hao, and X. Sha, “Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery,” Biomaterials, vol. 45, pp. 99–114, 2015. View at Publisher · View at Google Scholar · View at Scopus
  127. J. C. Leighton Jr. and L. J. Goldstein, “P-glycoprotein in adult solid tumors: expression and prognostic significance,” Hematology/Oncology Clinics of North America, vol. 9, no. 2, pp. 251–273, 1995. View at Google Scholar · View at Scopus
  128. E. K. Fetisova, A. V. Avetisyan, D. S. Izyumov, M. V. Korotetskaya, B. V. Chernyak, and V. P. Skulachev, “Mitochondria-targeted antioxidant SkQR1 selectively protects MDR (Pgp 170)-negative cells against oxidative stress,” FEBS Letters, vol. 584, no. 3, pp. 562–566, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. W.-B. Li, Y. Li, C. Yu, and Y.-M. He, “Reversal of multidrug resistance by the Chinese medicine Yiqi Jianpi Huaji decoction and the mechanism of action in human gastric cancer SGC7901/VCR Cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 390812, 11 pages, 2015. View at Publisher · View at Google Scholar
  130. S. Y. Eid, M. Z. El-Readi, M. L. Ashour, and M. Wink, “Fallopia japonica, a natural modulator, can overcome multidrug resistance in cancer cells,” Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 868424, 8 pages, 2015. View at Publisher · View at Google Scholar
  131. F. Chen, M. Zhuang, C. Zhong et al., “Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway,” Oncology Reports, vol. 33, no. 1, pp. 457–463, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. H. Sui, L.-H. Zhou, Y.-L. Zhang et al., “Evodiamine suppresses ABCG2 mediated drug resistance by inhibiting p50/NF-κB pathway in colorectal cancer,” Journal of Cellular Biochemistry, 2015. View at Publisher · View at Google Scholar
  133. C.-Z. Wang, X. Luo, B. Zhang et al., “Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells,” Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 69–79, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” The New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. B. Zhai and X.-Y. Sun, “Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma,” World Journal of Hepatology, vol. 5, no. 7, pp. 345–352, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. B. Zhai, F. Hu, X. Jiang et al., “Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma,” Molecular Cancer Therapeutics, vol. 13, no. 6, pp. 1589–1598, 2014. View at Publisher · View at Google Scholar · View at Scopus
  137. B. Zhai, F. Hu, H. Yan et al., “Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: the role of endoplasmic reticulum stress,” PLoS ONE, vol. 10, no. 9, Article ID e0138485, 2015. View at Publisher · View at Google Scholar
  138. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. Y.-C. He, F.-L. Zhou, Y. Shen, D.-F. Liao, and D. Cao, “Apoptotic death of cancer stem cells for cancer therapy,” International Journal of Molecular Sciences, vol. 15, no. 5, pp. 8335–8351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  140. D. E. Costea, O. Tsinkalovsky, O. K. Vintermyr, A. C. Johannessen, and I. C. Mackenzie, “Cancer stem cells—new and potentially important targets for the therapy of oral squamous cell carcinoma,” Oral Diseases, vol. 12, no. 5, pp. 443–454, 2006. View at Publisher · View at Google Scholar · View at Scopus
  141. Y. Chang, Y. Zhao, H. Zhan, X. Wei, T. Liu, and B. Zheng, “Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells,” Tumor Biology, vol. 35, no. 2, pp. 1075–1082, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. E. R. Carlson, D. Oreadi, and J. M. McCoy, “Nevoid basal cell carcinoma syndrome and the keratocystic odontogenic tumor,” Journal of Oral and Maxillofacial Surgery, vol. 73, no. 12, pp. S77–S86, 2015. View at Publisher · View at Google Scholar
  143. W. Li, Q. Wang, Q. Su et al., “Honokiol suppresses renal cancer cells' metastasis Via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling,” Molecules and Cells, vol. 37, no. 5, pp. 383–388, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. L. Wei, P. Chen, Y. Chen et al., “Pien Tze Huang suppresses the stem-like side population in colorectal cancer cells,” Molecular Medicine Reports, vol. 9, no. 1, pp. 261–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. M. A. Swartz, N. Iida, E. W. Roberts et al., “Tumor microenvironment complexity: emerging roles in cancer therapy,” Cancer Research, vol. 72, no. 10, pp. 2473–2480, 2012. View at Publisher · View at Google Scholar · View at Scopus
  146. T. Yin, S. He, T. Ye, G. Shen, Y. Wan, and Y. Wang, “Antiangiogenic therapy using sunitinib combined with rapamycin retards tumor growth but promotes metastasis,” Translational Oncology, vol. 7, no. 2, pp. 221–229, 2014. View at Publisher · View at Google Scholar · View at Scopus
  147. C.-Y. Wu, L.-H. Yang, H.-Y. Yang et al., “Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors,” Clinical Cancer Research, vol. 20, no. 3, pp. 644–657, 2014. View at Publisher · View at Google Scholar · View at Scopus
  148. C. M. Zegers, N. H. Rekers, D. H. Quaden et al., “Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects,” Clinical Cancer Research, vol. 21, no. 5, pp. 1151–1160, 2015. View at Publisher · View at Google Scholar
  149. Q. Huang, F. Li, X. Liu et al., “Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy,” Nature Medicine, vol. 17, no. 7, pp. 860–866, 2011. View at Publisher · View at Google Scholar · View at Scopus